Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease.
Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease.
复制标题
DOI：
10.1097/mco.0b013e32833b648e
复制
发表时间：
2010-09
影响因子：
3.1
通讯作者：
Hontecillas R
中科院分区：
文献类型：
--
作者：
Bassaganya-Riera J;Hontecillas R
炎症性肠病(IBD)是一种病因不明的、由免疫调节的衰弱疾病。目前的治疗方法是相当成功的，而且有显著的副作用。该综述的目的是总结目前对CLA和n-3多不饱和脂肪酸在IBD中抗炎作用机制的了解。针对过氧化物酶体增殖物激活受体(PPAR)的营养干预措施，如饮食共轭亚油酸(CLA)或n-3PUFA，已在IBD动物模型中证明了抗炎效果。尽管最近的一项人类研究结果表明，通过n-3多不饱和脂肪酸干预将n-3/n-6比率维持在0.65以上，IBD的缓解可以保持在0.65以上，但有关n-3PUFA的临床数据总体上仍不令人印象深刻。在小鼠中，共轭亚油酸通过激活PPARγ和调节调节性T细胞和巨噬细胞来预防炎症驱动的结直肠癌。CLA是一项正在进行的克罗恩病患者临床研究的对象。令人信服的证据表明，n-3多不饱和脂肪酸和共轭亚油酸在动物模型中预防或改善IBD。然而，这些基本知识还没有转化为新的以营养为基础的临床干预措施。对于这两种化合物，迫切需要进行安慰剂对照的大规模多中心临床试验。
Inflammatory bowel disease (IBD) is a debilitating and widespread immune-mediated illness of unknown etiology. Current treatments are modestly successful and with significant side effects. The purpose of this review is to summarize the current understanding of mechanisms of action underlying the anti-inflammatory actions of CLA and n-3 PUFA in IBD. Nutrition-based interventions that target peroxisome proliferator-activated receptors (PPARs) such as dietary conjugated linoleic acid (CLA) or n-3 PUFA have demonstrated anti-inflammatory efficacy in animal models of IBD. Clinical data on n-3 PUFA in IBD remains generally unimpressive, although results of a recent human study demonstrate that IBD remission can be maintained by maintaining the n-3/n-6 ratio over 0.65 via n-3 PUFA intervention. In mice, CLA prevented inflammation-driven colorectal cancer by activating PPAR γ and modulating regulatory T cells and macrophages. CLA is the subject of an ongoing clinical study in Crohn’s disease patients. Compelling evidence demonstrates that n-3 PUFA and CLA prevent or ameliorate IBD in animal models. However this basic knowledge has not been translated into novel nutrition-based clinical interventions. For both compounds there is an urgent need for placebo-controlled, large-scale, multi-center clinical trials.